Liraglutide, a human glucagon-like peptide-1 analogue, plays a role in reducing body weight in the patients with type 2 diabetes

VernacularTitle:人胰升糖素样肽1类似物利拉鲁肽减轻2型糖尿病患者体重的作用
Author: Dajin ZOU
Publication Type:Journal Article
Keywords: Obesity; Diabetes mellitus,type 2; Insulin resistance; Glucagon-like peptide-1; Liraglutide
From: Chinese Journal of Endocrinology and Metabolism 2011;27(8):703-706
CountryChina
Language:Chinese
Abstract: Obesity is associated with numerous metabolic abnormalities, including insulin resistance and type 2 diabetes. Losing weight is an effective way of improving insulin sensitivity, thus decreasing the risk of obesityassociated diabetes and chronic cardiovascular disease. There is evidence that Liraglutide, as a human glucagon-like peptide-1 ( GLP-1 ) analogue, either using alone or combining with other glucose-lowering drugs, has effect on improving glycemic control, protecting β-cell function, and reducing body weight via inhibiting feeding behavior and delaying gastrointestinal motility. Therefore, liraglutide is a new option for treating type 2 diabetes patients.